Please check your internet connection and try again.
# Tab%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520voihep
## Overview
Tab%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520voihep (tenofovir alafenamide/emtricitabine) is a fixed-dose combination antiviral medication used for the treatment of HIV-1 infection.
## Primary Indications
Treatment of HIV-1 infection in adults and pediatric patients (age and weight specific).
## Adult Dosing
One tablet (tenofovir alafenamide 25 mg/emtricitabine 200 mg) taken orally once daily.
## Pediatric Dosing
* **Pediatric patients weighing at least 35 kg:** One tablet (tenofovir alafenamide 25 mg/emtricitabine 200 mg) taken orally once daily.
* Dosing for pediatric patients weighing less than 35 kg is not established with this fixed-dose combination tablet.
## Dose Adjustments
No dose adjustment is necessary based on renal impairment. However, it is generally not recommended for patients with severe renal impairment (CrCl < 30 mL/min) due to potential accumulation. Consult local guidelines for specific recommendations in this population. No dose adjustment is necessary for hepatic impairment.
## Contraindications
* Hypersensitivity to emtricitabine, tenofovir alafenamide, or any component of the tablet.
## Adverse Effects
Common adverse effects include diarrhea, nausea, headache, and rash. More serious potential adverse effects include lactic acidosis, severe hepatomegaly with steatosis, immune reconstitution inflammatory syndrome (IRIS), and renal or bone toxicity (though less common with tenofovir alafenamide compared to tenofovir disoproxil fumarate).
## Key Drug Interactions
* **Strong CYP3A4 inducers** (e.g., rifampin, carbamazepine, phenytoin, St. John's wort) can decrease plasma concentrations of tenofovir alafenamide, potentially leading to loss of virologic response and resistance. Avoid concomitant use.
* **Other antiretrovirals:** Consult prescribing information for specific recommendations regarding coadministration with other HIV medications.
## Monitoring
* HIV-1 RNA (viral load)
* CD4+ cell count
* Renal function (serum creatinine, urinalysis)
* Liver function tests (AST, ALT)
* Bone mineral density (especially in patients with risk factors for fracture)
* Serum electrolytes
## Clinical Pearls
* Tab%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520voihep offers a lower risk of renal and bone toxicity compared to tenofovir disoproxil fumarate-based regimens.
* This fixed-dose combination should be taken as a complete regimen for HIV treatment.
* For pediatric patients under 35 kg, alternative tenofovir alafenamide-containing regimens may be necessary.
***
*This information is intended for clinical pharmacists and healthcare professionals. It is essential to consult the most current prescribing information and relevant clinical guidelines before initiating or modifying therapy.*
